Drug intelligence / Profile preview

MIC1045

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC1045 is a small molecule immuno-oncology drug under preclinical development by Micar21. It is designed to treat cancer metastasis by targeting the C-C chemokine receptor type 7 (CCR7). The drug is part of Micar21's internal drug discovery programs, leveraging computational chemistry and traditional approaches to develop best-in-class therapeutics.

Targets

CCR7 (C-C Motif Chemokine Receptor 7)

Beyond the preview

Go deeper on MIC1045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC1045.

Explore the full profile